Dynavax Technologies Co. (NASDAQ:DVAX) has earned an average rating of “Buy” from the seven ratings firms that are currently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $12.50.
Several brokerages have recently commented on DVAX. Zacks Investment Research upgraded shares of Dynavax Technologies from a “hold” rating to a “buy” rating and set a $4.50 price objective on the stock in a report on Friday, August 16th. BidaskClub upgraded shares of Dynavax Technologies from a “sell” rating to a “hold” rating in a report on Thursday. ValuEngine upgraded shares of Dynavax Technologies from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. William Blair restated a “buy” rating on shares of Dynavax Technologies in a report on Friday, August 16th. Finally, Royal Bank of Canada reduced their target price on shares of Dynavax Technologies to $13.00 and set an “outperform” rating on the stock in a report on Friday, May 24th.
In other Dynavax Technologies news, Director Francis Cano bought 16,667 shares of Dynavax Technologies stock in a transaction on Monday, August 12th. The shares were bought at an average cost of $3.00 per share, for a total transaction of $50,001.00. Following the acquisition, the director now directly owns 118,484 shares in the company, valued at $355,452. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Robert Coffman sold 32,218 shares of the stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $4.58, for a total transaction of $147,558.44. Following the sale, the senior vice president now owns 132,470 shares in the company, valued at $606,712.60. The disclosure for this sale can be found here. 4.90% of the stock is owned by corporate insiders.
Dynavax Technologies stock opened at $4.32 on Tuesday. The firm has a 50 day simple moving average of $3.51 and a 200-day simple moving average of $6.13. Dynavax Technologies has a 1-year low of $2.60 and a 1-year high of $14.35. The company has a debt-to-equity ratio of 19.95, a current ratio of 4.30 and a quick ratio of 3.47.
Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.03). Dynavax Technologies had a negative net margin of 781.10% and a negative return on equity of 304.71%. The firm had revenue of $8.30 million during the quarter, compared to analysts’ expectations of $8.24 million. During the same period last year, the company earned ($0.63) EPS. The business’s quarterly revenue was up 564.0% on a year-over-year basis. Equities analysts forecast that Dynavax Technologies will post -1.99 EPS for the current year.
Dynavax Technologies Company Profile
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.
Featured Story: How is a buy-side analyst different from a sell-side analyst?
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.